A Review on Emerging Biomarkers for Early Detection of Ovarian Cancer

Published on:January 2024
Indian Journal of Pharmacy Practice, 2024; 17(1):17-20
Review Article | doi:10.5530/ijopp.17.1.3


A Review on Emerging Biomarkers for Early Detection of Ovarian Cancer


Authors and affiliation (s):

Blessy Fernandes

Department of Pharmacy Practice, Srinivas College of Pharmacy, Mangalore, Karnataka, INDIA.

Abstract:

Ovarian cancer is a serious and complex disease that primarily affects the ovaries. Detecting it in its early stages is important for successful treatment and improved outcomes. While common symptoms such as abdominal pain, bloating, and changes in bowel or urinary habits may raise suspicion, they are often nonspecific, making early diagnosis challenging. Age, family history, and gene mutations are some common risk factors. Emerging biomarkers for early detection of ovarian cancer are CA-125, HE4, osteopontin and genetic testing. Medical professionals usually perform a combination of imaging tests and biopsy to confirm the presence of ovarian cancer. Surgery, chemotherapy, and targeted therapy are some of the possible treatments that can be chosen depending on the stage and type of cancer. Early detection and efficient treatment depend on regular checkups and awareness of possible signs.

Keywords: Biomarkers, Detection, Ovarian cancer, risk factors




 

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 2008.

DOI HISTORY

IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs